GlobeNewswire

Cisco Leadership In Automation Continues With New Network Automation Portfolio for Service Providers

Dela

Company launches industry's most comprehensive closed-loop multi-vendor, multi-domain automation solution

 

SAN JOSE, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Cisco today introduced its new Cisco Crosswork Network Automation software portfolio to improve how global service providers run their large-scale networks. The solutions are designed to work together to offer greater network visibility at scale (mass awareness), data-driven insights (augmented intelligence) and outcome-based automation (proactive control). 

With 27 billion devices and connections1 expected to be running on service provider networks by 2021, the pressure is on for industry adoption of complete lifecycle network automation and intent-based networking to help networks predict change and react in near real time.

Traditional operations staff will not be able to keep up with adding nearly 10 percent more devices every year without changing how they work. When Cisco automation is utilized, typical results include a 70 percent improvement in operational efficiency, 30 percent revenue uplift and a 40 percent improvement in customer satisfaction2.

The new Cisco Crosswork Network Automation software portfolio helps innovative global service providers like Telstra and many othersautomate their networks and explore how to effectively extract and manage huge amounts of data to help their networks react to common events and impending security threats.

This new portfolio offers service providers a single point of integration with zero-touch telemetry, machine learning intuition, open APIs and automated actions that offer a simpler experience.  It is backed by Cisco Services to assist customers with planning, customization and implementation.

New software technologies available today include:

  • Cisco Crosswork Change Automation: Automated operations application that enables large-scale change and closed-loop control
  • Cisco Crosswork Health Insights: Smart sensors, smart alerts and smart remediation to monitor and optimize networks
  • Cisco Crosswork Data Platform: Featuring both an OpenSource and commercial-class data analytics platform
  • Cisco Crosswork Network Insights: Cloud-based analytics solution for solving large-scale routing issues
  • Cisco Crosswork Situation Manager: Machine learning-based event correlation featuring social tools such as chat functions to solve repair issues quickly.

The Cisco Crosswork Network Automation solution extends capabilities of the Cisco Network Services Orchestrator (NSO), offering the industry's most comprehensive closed-loop multi-vendor, multi-domain automation solution, with service orchestration and automation applications that support third-party solutions with open APIs.

Solving Customer Challenges  
With this new portfolio, Cisco is uniquely offering its service provider customers easy onboarding into the network automation process. Key customer challenges the Cisco Crosswork Network Automation portfolio addresses include:

  • Human driven network changes are error prone, time consuming, and lack comprehensive validation.
    • Cisco Network Services Orchestrator transforms network changes into intent-driven deployments with automatic validation
  • Data silos make network data impossible to analyze and correlate.
    • Cisco Crosswork Data Platform creates a single point to seamlessly collect, analyze, and visualize network data across multiple services and domains
  • Customer experience suffers when variations in network quality go unnoticed.
    • The Cisco Crosswork Data Platform, combined with Cisco Crosswork Health Insights, utilizes real-time visualization with analytics to provide unparalleled insight into network performance.
  • The time needed to manually identify network problems results in significant business impacts when outages occur.
    • Cisco Crosswork Situation Manager uses artificial intelligence algorithms to automatically triangulate faults across multiple network domains, drastically reducing the time to isolate network outages, and provide root cause analysis to prevent future outages
  • Remediating network problems is a slow and manual process.
    • Cisco Crosswork Change Automation uses analytics enhanced closed-loop automation to automatically remediate network issues as they happen
  • Global Routing Scale errors can cause dramatic outages.
    • Cisco Crosswork Network Insights enables a cloud-first approach for resolving challenges in the rapidly changing global routing environment
  • Networks are not continually optimized for business and service needs.
    • Cisco WAN Automation Engine (WAE) and XR Traffic Controller (XTC) use advanced telemetry and analytics to improve network performance in real time without human intervention

"As we remain focused on building Australia's leading network of the future, we are committed to delivering superior quality networked experiences to our customers," said David Robertson, Director, Network Transport & Routing Engineering, Telstra. "We are equally focused on anticipating the challenges and opportunities that affect our business goals. Our work with Cisco to reinvent our network operations through orchestration, automation and advanced data models offers us valuable insight for mass data collection, applying analytics and machine learning, and taking decisive action through automation."

"Only Cisco can offer this comprehensive and holistic automation approach to solve challenges of today's mass scale infrastructure," said Jonathan Davidson, senior vice president and general manager, Service Provider Networking, Cisco. "Our primary goal for network automation is to help our customers turn growing pains into growing profit, and streamline operations so they can spend less time on tactical 'firefighting' and more time on identifying and trialing new revenue streams."

Cisco is leading disruption in the industry with our technology innovations in systems, silicon, optics and security, and our unrivalled expertise in mass-scale networking, automation, optical, cable access, video, and mobility. Together with our portfolio of professional services, we can enable service providers and media and web companies to reduce cost and complexity, help secure their networks and grow revenue. 

Supporting Resources

RSS Feed for Cisco:  http://newsroom.cisco.com/dlls/rss.html

About Cisco
Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at newsroom.cisco.com and follow us on Twitter at @Cisco.

Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company.

Press Contact
Sara Cicero, Service Provider PR, Cisco, stutzes@cisco.com

_________________________

1 Cisco Visual Networking Index Forecast, 2016-2021
2 Cisco BTA analysis on automation




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum